HCM
GALT icon

Howard Capital Management’s Galectin Therapeutics GALT Stock Holding History

Howard Capital Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,000
Closed -$16K – 37
2022
Q1 		$16K Buy
+10,000
New +$19.4K ﹤0.01% 39

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Howard Capital Management's GALT Position: Q2 2022 in Review

Howard Capital Management sold out of Galectin Therapeutics (GALT) in Q2 2022, closing a stake of 10,000 shares — an estimated $16K sold.

Howard Capital Management first reported a position in GALT in Q1 2022 and held it in 1 quarter. The position peaked at $16K in Q1 2022. 60 funds tracked by Wall St. Rank hold GALT as of Q2 2022.

  • Howard Capital Management reported no remaining Galectin Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Howard Capital Management sold 10,000 Galectin Therapeutics shares in Q2 2022, an estimated $16K.
  • Howard Capital Management first reported a position in Galectin Therapeutics in Q1 2022 and held it in 1 quarter.
  • Howard Capital Management's Galectin Therapeutics position peaked at $16K in Q1 2022.
  • 60 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2022.

Based on Howard Capital Management's 13F filing for Q2 2022, filed 27 Jul 2022.